News Blocking Molecule Prevents B-cells from Entering Brain and Promoting MS Progression, Study Reports

News NMSS Awards $495K to Study Biomarkers in Phase 2 Trial of NurOwn in Progressive MS

Columns, The MS Wire - A Column by Ed Tobias MS News that Caught My Eye Last Week: Mayzent in EU for SPMS; Depression, Fatigue, and Quality of Life; Acthar Gel; Soothie Cushion

News Novel MRI Marker Better at Predicting MS Progression, Study Reports

News, SPMS Mayzent Approved in Australia as First Treatment for Secondary Progressive MS

Columns, Fall Down, Get Up Again- a Column by John Connor This Could Be the Last Time

Alexa, News, SPMS CHMP Favors Mayzent as Oral Treatment Specifically for Active SPMS Patients in EU

Columns, The MS Wire - A Column by Ed Tobias Is It Good that Google Is Crunching Our Healthcare Data?

News Weill Neurohub Unites 3 Academic Centers with DOE Scientists to Advance Tools, Treatments for MS and Other Ills

News Depression, Fatigue Influence Health-related Quality of Life More Than Physical Impairment of MS, Study Reveals

Columns, MS in Moderation – a Column by Tamara Sellman Need to Know: 21st-century Medicine Models

Columns, Silver Linings - a Column by Jennifer Powell Filtering Ads and Choosing What’s Best

News Vumerity’s $88,000 List Price Not What ‘We Had Hoped,’ National MS Society Says

News 7T MRI Reveals New Insights into Some RRMS Features

News Single Dose of CD45-ADC Resets the Immune System, Delays the Onset of MS in Mice

News Sativex, Cannabis Extract for MS Spasticity, Now Available to Select Patients in England

News Long-term IFN-Beta Treatment Normalizes Immune Balance in RRMS, Study Shows

News Acthar Gel Quite Effective at Resolving Relapses as Alternative to Corticosteroids, Study Reports

Columns, The MS Wire - A Column by Ed Tobias MS News that Caught My Eye Last Week: EU Lemtrada Safety Guidance, Targeted Treatment Project, SPMS Patients Unaware of Diagnosis

News, SPMS Early Damage on Brain Scans and Greater 5-Year Disability Help Predict 30-Year Outcomes in MS, Study Finds

News Low Neurite Density in Spinal Cord Linked to Greater Physical Disability in RRMS Patients

A Life in Letters – a Column by Jamie Hughes, Columns Simple Signs with Messages of Hope Resonate with Me

Columns, Fall Down, Get Up Again- a Column by John Connor MS Really Enjoys Hitting Below the Belt

Columns, The MS Wire - A Column by Ed Tobias Top MS Worries Highlight the Need for a Comprehensive Care Program

News ‘Soothie Cushion’ Designed to Regulate Body Temperature in Travelers With MS, Other Disabilities

News 2 Potassium Channels Key to Fast Transmission of Impulses Along Myelin-rich Nerve Fibers, Study Shows

Columns, MS in Moderation – a Column by Tamara Sellman Need to Know: Does Brain Matter Matter?

Columns, Silver Linings - a Column by Jennifer Powell Choosing Calm Over Chaos: Quieting Myself While Living with SPMS

News Generic Version of Gilenya, pms-Fingolimod, Now Available for RRMS Patients in Canada

News Siemens Healthineers Joins with Quanterix to Develop Blood Tests for NfL Levels

Columns, Making a Difference - a Column by Cathy Chester. The Past Gives Us Hope for the Future

News Specific FOXP3 Mutation Linked to Greater Likelihood of MS in Brazilian Women, Study Reports

News European 3TR Project Unites Experts in Effort to Make Treatment More Personal and Effective

News Employed MS Patients Have Lower Productivity, Reduced Health-related Quality of Life, Study Shows

News EMA Safety Group Advises Lemtrada Be Limited to ‘Highly Active’ RRMS Patients at Hospitals with ICUs

Columns, The MS Wire - A Column by Ed Tobias MS News that Caught My Eye Last Week: Vumerity Approval, Low Antibody Levels in MS Patients, GA Depot Trial, Tecfidera Study

News Teva-Fingolimod, Generic and Bioequivalent Version of Gilenya, Available in Canada

News Mutations in 3 Genes Linked to Vision Loss and MS Severity in Hopkins Study

Columns, The MS Wire - A Column by Ed Tobias My Lemtrada Journey: Observations at 18 Months After Round 2

News, SPMS Study: 40% of SPMS Patients in Italy and Germany Unaware of Diagnosis

News Interferons Superior to Glatiramer Acetate, and Tysabri More Effective than Gilenya for RRMS, Real-world Study Finds

Sponsored Content The brain is made up of two types of tissue: grey matter and white ...

Columns, MS in Moderation – a Column by Tamara Sellman Need to Know: What Is Lesion Load?

Columns, Silver Linings - a Column by Jennifer Powell MS and Mythological Mends: Hope Is My Cure for Today

News Medicinal Cannabinoids Not Effective for Mental Disorders, Small Relief on MS Anxiety, Analysis Suggests

News Brain Bank at Harvard Gets Potential $12.8M from NIH to Support Brain Donations for MS and Other Research

News, SPMS Vumerity Approved in US as Treatment for RRMS and Active SPMS

News First Relapsing MS Patient Enrolled in Phase 3 Trial of Mapi Pharma’s Once-monthly Glatiramer Formulation

News Unemployment Risk Factors in MS Vary with Age, Study Suggests

News UV-B Light Prevents MS Symptoms in Mice Independently of Vitamin D, Study Finds

News Levels of Infection-fighting Antibodies Low in Blood of People with MS, Study Finds

Columns, The MS Wire - A Column by Ed Tobias MS News that Caught My Eye Last Week: Cognitive Impairment, Genetic Variant Risk Factor, Protein Biomarkers, Gilenya Study

News AP-1 Transcription Factor Family is Critical for Healthy T-cell Development, Study Says

News Altered Fear Response, Changes in Brain Chemistry Seen in Mice with Poor Gut Microbiota

A Life in Letters – a Column by Jamie Hughes, Columns Mystery Keeps Me Pushing Forward: I Wonder What I’ll Do Next

Columns, Fall Down, Get Up Again- a Column by John Connor Pip, Pip, Hooray! Months of Work and Worry Pay Off

Columns, The MS Wire - A Column by Ed Tobias Am I Too Old for Aggressive MS Treatment?

News Higher Intellectual Ability, Early-life Physical Activity May Protect Against Cognitive Impairment in MS, Study Suggests

News Twice Daily Dosing and Side Effects Top Reasons Patients Seen to Stop Tecfidera in Small Study

Columns, MS in Moderation – a Column by Tamara Sellman Need to Know: How MS Affects Memory

Columns, Silver Linings - a Column by Jennifer Powell MS and Anxiety: Be Kind to Yourself and Ask for Help

News SARM1 Inhibitors Protect Neurons from Damage in Mice and Cell Cultures, Results Presented at Neuroscience 2019 Show

News Potential RRMS Fumarate Treatment Free of ‘Flush’ Effect to Enter Trial in 2020, Vitalis Says

News, SPMS NfL and CHI3L1 Work as Biomarkers of Disease Activity and Progression in MS, Study Says

News MS Among Research and Discussion Topics at 24th World Congress of Neurology

Columns, Patiently Awakened - A Column by Teresa Wright-Johnson Why My Body Is Not My Adversary

News Endothelin-1 a Potential Biomarker of Severity and Recovery from Optic Neuritis in MS, Study Suggests

News Long-term Gilenya Treatment Safe and Effective for Relapsing MS Patients, Phase 3 Trial Shows

Columns, The MS Wire - A Column by Ed Tobias MS News that Caught My Eye Last Week: Injectable DMTs, Ofatumumab ‘Success Story,’ MS and Night Shift Work, MS Biomarker Study

News GAL Gene Variant May Put MS Patients at Risk for Rapidly Progressive Disease, Study Suggests

News National MS Society Awards $14.6M Supporting 43 New Research Projects

Columns, Fall Down, Get Up Again- a Column by John Connor This Week, I Feel Like I’m Growing Up Again

Columns, The MS Wire - A Column by Ed Tobias Pushing to Put a Symbol for Invisible Disabilities on Driver’s Licenses

News #ECTRIMS2019 – Are Injectables Inappropriate for Active Relapsing MS Treatment?

News MS Mindshift Brings Brain Health Effort, ‘Brain Bulb’ Hot Air Balloon to Atlanta Area Festival

Columns, MS in Moderation – a Column by Tamara Sellman Need to Know: Why Do People Have Seasonal Temperature Sensitivity?

Columns, Silver Linings - a Column by Jennifer Powell Marriage and Multiple Sclerosis: Lessons in Love

News Interleukin-22 May Be Biomarker to Monitor How Well RRMS Patients Respond to Therapy

News Rituximab Linked to Greater Risk of Infections in MS Patients in Real-world Swedish Study

News Tysabri Treatment Leads to Disease Activity-free Status in Patients with Pediatric-onset MS

News NMSS Awards $339K to Phase 2 Trial of Potential Remyelination Agent, Clene Nanomedicine Announces

News #ECTRIMS2019 – Ofatumumab Part of ‘Magnificent Success Story’ for MS, ASCLEPIOS Trial Investigator Says

News Immunic Therapeutics Fully Enrolls Phase 2 Trial of Oral IMU-838, Potential RRMS Treatment

Columns, The MS Wire - A Column by Ed Tobias MS News that Caught My Eye Last Week: Mavenclad and Ocrevus Use Rising in EU, Ampyra Patent Appeal Denied, Exercise and MS Pilot Study

News Decades of Night Work Tied to Nearly 3 Times Higher MS Risk, Studies in Nurses Suggest

News Metformin Works to Promote Remyelination in Ways Similar to Fasting, Study Says

A Life in Letters – a Column by Jamie Hughes, Columns ‘The Land Is Better’: Embracing Highs and Lows

Columns, Fall Down, Get Up Again- a Column by John Connor I’m a Big Boy Now

Columns, The MS Wire - A Column by Ed Tobias It’s Not All in Your Head

News Mavenclad, Ocrevus Use Rising in EU as Injectables and Tysabri Decline, Spherix Reports

News MS Society in UK Opens ‘Stop MS Appeal,’ £100M Fundraiser to Better Treat Disease

Columns, MS in Moderation – a Column by Tamara Sellman Need to Know: MS and Respiratory Viruses

News Blocking LRP1 May Halt Inflammation, Promote Remyelination, Mouse Study Suggests

News Ills Like Depression, Hypertension More Common in MS Patients Than Others in US, Blue Cross Report Finds

News US Supreme Court Denies Acorda Appeal on Ampyra Patents, Supporting Generic Versions

News CMSC Grant to Support Kessler Foundation Study of Low-risk Exercise in MS

News Targeting Toxic T Helper Cells – Those with CXCR6 Receptor – Seen to Prevent MS in Mouse Model

News Structure and Workings of Receptor Tied to Inflammation and Cell Death Seen for First Time

Columns, The MS Wire - A Column by Ed Tobias MS News that Caught My Eye Last Week: Rituximab vs. Ocrevus

News RRMS Patients Not Using DMTs More Likely to Have Been Misdiagnosed, Cite Poorer Relationships with Doctors, Survey Says